Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cangrelor on Top of Anticoagulation in MI-Related Cardiogenic Shock/CA Receiving VA-ECMO and/or Impella Support
2024-512829-81-00Phase 2Authorised
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- May 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cangrelor in myocardial infarction (MI), cardiogenic shock, cardiac arrest (SCA) and 1 more, sponsored by IRCCS Ospedale San Raffaele. Primary endpoints: Thrombotic and bleeding adverse events during cangrelor infusion and Major bleeding events (BARC type 3b or 5). Planned start May 2024; status: authorised.
02
Drugs
cangrelor
03
Conditions
myocardial infarction (MI)cardiogenic shockcardiac arrest (SCA)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2024-512829-81-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512829-81-00.